- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 27.01. | FDA clears monthly dosing of Alzheimer's drug Leqembi | ||
| 27.01. | Muscle-building drug improves body composition in obesity trial, Veru says | ||
| 27.01. | Retail pharmacies: Biopharma's bridge to better patient experiences and outcomes | ||
| 27.01. | Are we overlooking something critical in cell and gene therapy research? | ||
| 24.01. | Sara Brenner, FDA device official, named agency's acting head | ||
| 24.01. | Novo shares climb on early data for dual-acting obesity drug | ||
| 24.01. | The biopharma industry outlook on 2025: Uncertainty and change | ||
| 24.01. | Mixed results for Keytruda; AbbVie to work with Neomorph | ||
| 24.01. | Ascentage prices first biotech IPO of 2025, raising $126M | ||
| 23.01. | Senate sets date to vet RFK Jr.'s nomination to lead HHS | ||
| 23.01. | AI in medtech is taking off. Here are 4 trends to watch in 2025. | ||
| 23.01. | BridgeBio's Neil Kumar on an underdog drug launch and wooing deal-hungry investors | ||
| 22.01. | Intellia makes progress on HAE study; 2 more China drug deals | ||
| 22.01. | J&J joins Pfizer in detailing impact of Part D redesign | ||
| 22.01. | J&J oncology sales grow, but shares slide on outlook | ||
| 21.01. | AstraZeneca, Daiichi's Enhertu successor gets first FDA OK in breast cancer | ||
| 21.01. | Moderna gets $590M from US government for bird flu vaccine | ||
| 21.01. | Trump reverses Biden healthcare directives, orders WHO withdrawal | ||
| 21.01. | Sionna, Odyssey join queue of biotechs testing investors' IPO interest | ||
| 21.01. | What will 2025 hold for biopharma? | ||
| 17.01. | Medicare will negotiate Novo's GLP-1 drug price. Here's what that means for Ozempic, Wegovy. | ||
| 17.01. | Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs | ||
| 17.01. | Ozempic, Ibrance among next drugs picked by Medicare for price talks | ||
| 16.01. | 'The bar has risen': China's biotech gains push US companies to adapt | ||
| 16.01. | Roche's new deals head tries to navigate a more 'complicated' and 'expensive' biotech world |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
